801 The anti-tumor efficacy of immunogenic chemotherapy is enhanced by the dual A2aR/A2bR antagonist etrumadenant, relieving the necessity for an extended chemotherapy regimen

Authors :: Daniel DiRenzo
Dana Piovesan
Ferdie Soriano
Livia Yamashiro
Janine Kline
Dillon Miles
Ehesan Sharif
Manmohan Leleti
Matthew Walters
Source :: Regular and Young Investigator Award Abstracts.
Publication Year :: 2022
Publisher :: BMJ Publishing Group Ltd, 2022.

Full Text Access

Tools